PHBBF Financials: Pharmaron Beijing Co., Ltd. AI Analysis

Home

Stock

PHBBF

Financials

PHBBF Financial

Pharmaron Beijing Co., Ltd.

$1.93

At close: Mar 27, 16:00:00 GMT-4

$1.93

Post-market: Mar 27, 20:00:00 GMT-4

Overview Forecast Earnings Dividends Financials

Income

Balance sheet

Cash flow

Annual

Quarterly

PHBBF Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	13,544	12,275	11,537	10,266	7,443	5,133
Revenue Growth (YoY)	15%	6%	12%	38%	45%	37%
Cost of Revenue	9,011	8,091	7,422	6,501	4,767	3,214
Gross Profit	4,532	4,184	4,115	3,764	2,676	1,918
Selling, General & Admin	1,998	1,772	1,766	1,640	977	720
Research & Development	528	432	418	261	135	91
Operating Expenses	2,528	2,385	2,330	2,041	1,165	832
Other Non Operating Income (Expenses)	-22	-4	-10	-23	-3	-4
Pretax Income	1,798	2,091	1,837	1,666	1,910	1,319
Income Tax Expense	387	377	256	314	290	172
Net Income	1,512	1,793	1,601	1,374	1,661	1,172
Net Income Growth	-20%	12%	17%	-17%	42%	113.99%
Shares Outstanding (Diluted)	1,763.38	1,773.31	1,772.52	1,776.27	1,819.77	793.2
Shares Change (YoY)	0%	0%	0%	-2%	129%	20%
EPS (Diluted)	0.85	1.01	0.9	0.77	0.91	1.48
EPS Growth	-19%	12%	17%	-15%	-38%	78%
Free Cash Flow	800	536	-111	-807	-34	332
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	33.46%	34.08%	35.66%	36.66%	35.95%	37.36%
Operating Margin	14.78%	14.64%	15.47%	16.77%	20.28%	21.15%
Profit Margin	11.16%	14.6%	13.87%	13.38%	22.31%	22.83%
Free Cash Flow Margin	5.9%	4.36%	-0.96%	-7.86%	-0.45%	6.46%
EBITDA	--	2,058	2,025	1,917	1,625	1,173
EBITDA Margin	--	16.76%	17.55%	18.67%	21.83%	22.85%
D&A For EBITDA	--	260	240	195	115	87
EBIT	2,003	1,798	1,785	1,722	1,510	1,086
EBIT Margin	14.78%	14.64%	15.47%	16.77%	20.28%	21.15%
Effective Tax Rate	21.52%	18.02%	13.93%	18.84%	15.18%	13.04%

Follow-Up Questions

What are Pharmaron Beijing Co., Ltd.'s key financial statements?



According to the latest financial statement (Form-10K), Pharmaron Beijing Co., Ltd. has a total asset of $23,927, Net profit of $1,793

What are the key financial ratios for PHBBF?



Pharmaron Beijing Co., Ltd.'s Current ratio is 2.32, has a Net margin is 14.6, sales per share of $6.92.

How is Pharmaron Beijing Co., Ltd.'s revenue broken down by segment or geography?



Pharmaron Beijing Co., Ltd. largest revenue segment is Laboratory Services, at a revenue of 7,046,874,518 in the most earnings release.For geography, North America is the primary market for Pharmaron Beijing Co., Ltd., at a revenue of 7,852,729,440.

Is Pharmaron Beijing Co., Ltd. profitable?



yes, according to the latest financial statements, Pharmaron Beijing Co., Ltd. has a net profit of $1,793

Does Pharmaron Beijing Co., Ltd. have any liabilities?



yes, Pharmaron Beijing Co., Ltd. has liability of 10,308

How many outstanding shares for Pharmaron Beijing Co., Ltd.?



Pharmaron Beijing Co., Ltd. has a total outstanding shares of 1,778.19

Key Stats

Prev.Close

$1.93

Open

$1.93

Day's Range

$1.93 - $1.93

52 week range

$1.93 - $1.93

Volume

100

Avg.Volume

Dividend yield

EPS (TTM)

0.12

Market Cap

$694.7M

What is PHARMARON BEIJING CO LTD?

Pharmaron Beijing Co Ltd is a CN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Beijing, Beijing and currently employs 21,370 full-time employees. The company went IPO on 2019-01-28. Pharmaron Beijing Co Ltd is a China-based company mainly engaged in pharmaceutical research and development. The firm operates through five segments. The Laboratory Services segment includes laboratory chemistry and bioscience services, covering small molecule drugs, oligonucleotides, peptides, antibodies, antibody-drug conjugates, and cell and gene therapy products. The Chemical and Formulation Process Development and Manufacturing Services segment includes active pharmaceutical ingredient process development and manufacturing, as well as preformulation and formulation development. The Clinical Research Services segment includes international and domestic clinical research services. The Large Molecule and Cell and Gene Therapy Services segment includes large molecule drug discovery, development, and manufacturing services, as well as cell and gene therapy laboratory and gene therapy drug development and manufacturing services. The firm also operates through the others segment.



Features

AI Copilot for Stock & Crypto

Resources